Key result
Arterial stenotic thrombosis is driven by shear stress-induced platelet activation and serotonin release, suggesting 5HT2A receptor antagonists as a potential targeted treatment without bleeding risk.
Answers are grounded in this paper and cite their sources.
This commentary highlights the role of shear stress and serotonin in arterial stenotic thrombosis, proposing 5HT2A antagonists as a potential alternative to dual antiplatelet therapy to avoid bleeding complications.
Current practice in arterial disease is to establish the site of stenosis, to dilate the stenosis with angioplasty or surgical bypass, and to try to maintain the integrity of the arterial lumen with stents. There are either bare stents or drug eluting stents which are more thrombogenic requiring long term dual antiplatelet therapy with its risk of increased bleeding. For coronary disease, this is called Percutaneous Coronary Intervention (PCI).
No takes yet. Share an insight, caveat, or question.
Mark I. M. Noble (2018) conducted an editorial in Arterial Stenotic Thrombosis. 5HT2A receptor antagonists was evaluated. Arterial stenotic thrombosis is driven by shear stress-induced platelet activation and serotonin release, suggesting 5HT2A receptor antagonists as a potential targeted treatment without bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: